拉米夫定联合博尔泰力治疗慢性乙型肝炎临床研究

To evaluate the effect of the treatment of chronic hepatits B with lamivudine combined with marine injection.60 patients with chronic hepatitis B as defined by positive HBeAg and HBVDNA and elevated ALT were enrolled and randomized into lamivudine combined with marine injection (LM) group and lamivudine (L) group.32 patients received lamivadine 100mg daily and marine injection 400mg im daily, and 28 paitents only received lamivudine 100mg daily.The efficacy and safty were evaluated with clinical, biochemical, and virological parameters.After 3 months treatment, HBV-DNA response (serum HBV-DNA negative) rate was no difference between LM group and L group: (93.75% vs 89.29%, P>0 05) .However, HBeAg negative rate was higher in LM group than L group: (50% vs 17.85%, P<0 01) , ALT normalization rate in LM goup was higher than in L group (81.25% vs 50.0%, P<0 05) .So we came to the conclussion that lamivudine combined with marine injection can effectively enhance HBeAg negative rate and ALT normalization rate, then the treatment course of lamivudine in chronic hepatits B would be shortened.